Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
Date:11/24/2008

DETROIT, Nov. 24 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Alternext US: CPD) announced today that it has timely submitted its response to the FDA warning letter that was received on October 31, 2008. In the warning letter, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008.

As previously disclosed, the warning letter was issued as a follow up to the last FDA inspection of the Company's manufacturing facility in Detroit, Michigan which was initiated in May 2008. Until the Company's responses to the observations have been clarified and explanations provided to the satisfaction of the FDA, the FDA may in the near term withhold approval of pending new drug applications listing the facility as the manufacturer. The Company's sales of current products continue in the normal course of business.

The Company is committed to working cooperatively and expeditiously with the FDA to resolve the matters indicated in its letter. The Company has requested a meeting with the FDA as a follow up to its response. Caraco believes it has addressed the concerns in the warning letter appropriately.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
2. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
3. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
4. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
7. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
8. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
9. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
10. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill the ... amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates ... be set up in a matter of minutes, or even seconds. The SAFETY STRAP ...
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... said an inventor from Winchester, Va. "I thought that if the nebulizer had a ... treatments rather than fearing them." , He developed the patent-pending NEBY to avoid the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking ... registration today for its 33rd Annual Issues & Research Conference, March 2-3, ... theme of the conference is “Persistent Challenges and New Opportunities: Using Research to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... FRISCO, Texas , Dec. 8, 2016 /PRNewswire/ ... new program that brings leading-edge laboratory services and ... the United States , allowing more doctors ... and health care management solutions. Logo ... Hospital systems, under pressure to ...
(Date:12/8/2016)... , December 8, 2016 Information products ... metrics in Scopus , the world,s largest abstract ... access to comprehensive metrics for journals from over 5,000 publishers. The ... which journals to subscribe to and when to adjust a journal,s ... , , ...
Breaking Medicine Technology: